
ATLANTA ? Five years of breast cancer adjuvant therapy with an aromatase inhibitor, can lead to a 6% to 7% loss of bone mineral density, a trigger for osteoporosis for women who are borderline osteopenic when they begin treatment, investigators reported here.
